Abstract Knowledge of pancreatitis in the 20th century was shaped predominantly by animal
data and clinical trials. Several large general population-based cohort studies and …

Post-ERCP pancreatitis (PEP) is the most common serious adverse event attributed to the
procedure, resulting in annual estimated costs exceeding 150 million dollars in the United …

Prophylaxis 1 ESGE recommends routine rectal administration of 100 mg of diclofenac or
indomethacin immediately before endoscopic retrograde cholangiopancreatography …

Common bile duct stones (CBDS) are estimated to be present in 10–20% of individuals with
symptomatic gallstones. They can result in a number of health problems, including pain …

This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy
(ESGE). It provides practical advice on how to achieve successful cannulation and …

This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy
(ESGE). It addresses the prophylaxis of post-endoscopic retrograde …

Even though considered safe, endoscopic retrograde cholangiopancreatography (ERCP) is
among the endoscopic procedures associated with the highest rate of complications. Post …

Background Rectal indometacin decreases the occurrence of pancreatitis after endoscopic
retrograde cholangiopancreatography (ERCP). However, the population most at risk and the …

Background Pancreatitis is the most common complication of endoscopic retrograde
cholangiopancreatography (ERCP). Prophylactic rectal administration of non-steroidal anti …

Background and Aims Diclofenac and indomethacin are the most studied drugs for
preventing post-ERCP pancreatitis (PEP). However, there are no prospective, randomized …